Cytomegalovirus Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cytomegalovirus infections markets are expected to exhibit a CAGR of 4.32% during 2024-2034.
The cytomegalovirus infections market has been comprehensively analyzed in IMARC's new report titled "Cytomegalovirus Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cytomegalovirus infections refer to medical conditions that are caused by the cytomegalovirus, a member of the herpesvirus family. This disease can be spread through various routes, including direct contact with bodily fluids, such as saliva, urine, breast milk, blood, semen, vaginal secretions, etc. It can also be transmitted from mother to fetus during pregnancy or through organ transplantation. The infection can manifest in several ways, depending on the patient's immune status. Some common symptoms of the ailment include fever, fatigue, muscle aches, sore throat, swollen glands, general malaise, gastrointestinal issues, inflammation of the retina and liver, etc. Cytomegalovirus infections are typically diagnosed through a combination of clinical evaluation, laboratory testing, and medical history review. The healthcare provider may perform blood workups involving DNA polymerase chain reaction to detect the presence of viral genetic material in the blood and confirm a diagnosis among patients. In some cases, if the infection affects specific organs or tissues, a biopsy may be recommended to obtain a sample for laboratory analysis and rule out other causes of the underlying symptoms.
The increasing prevalence of exposure to infected fluids through activities like kissing, sexual contact, sharing utensils or drinks, etc., is primarily driving the cytomegalovirus infections market. In addition to this, the rising cases of weakened immune systems, in which the number and function of white blood cells are reduced, resulting in a decreased ability to control diseases, is also creating a positive outlook for the market. Moreover, the widespread adoption of antiviral drugs, including ganciclovir, valganciclovir, foscarnet, etc., since they work by inhibiting the replication of the virus, is further bolstering the market growth. Apart from this, the escalating application of intravenous immunoglobulin therapy that modulates the body's defense system, thereby potentially reducing inflammation and preventing or minimizing organ damage, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hematopoietic stem cell transplants to treat the ailment, owing to their several associated benefits, such as effectively eliminating the viral load and improving overall patient outcomes, is expected to drive the cytomegalovirus infections market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cytomegalovirus infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cytomegalovirus infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cytomegalovirus infections market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cytomegalovirus infections market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cytomegalovirus infections market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cytomegalovirus infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cytomegalovirus infections market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cytomegalovirus infections market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cytomegalovirus infections market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections across the seven major markets?
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cytomegalovirus infections across the seven major markets?
What is the size of the cytomegalovirus infections patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cytomegalovirus infections?
What will be the growth rate of patients across the seven major markets?
Cytomegalovirus Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cytomegalovirus infections drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cytomegalovirus infections market?
What are the key regulatory events related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by status related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by phase related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by route of administration related to the cytomegalovirus infections market?
The cytomegalovirus infections market has been comprehensively analyzed in IMARC's new report titled "Cytomegalovirus Infections Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cytomegalovirus infections refer to medical conditions that are caused by the cytomegalovirus, a member of the herpesvirus family. This disease can be spread through various routes, including direct contact with bodily fluids, such as saliva, urine, breast milk, blood, semen, vaginal secretions, etc. It can also be transmitted from mother to fetus during pregnancy or through organ transplantation. The infection can manifest in several ways, depending on the patient's immune status. Some common symptoms of the ailment include fever, fatigue, muscle aches, sore throat, swollen glands, general malaise, gastrointestinal issues, inflammation of the retina and liver, etc. Cytomegalovirus infections are typically diagnosed through a combination of clinical evaluation, laboratory testing, and medical history review. The healthcare provider may perform blood workups involving DNA polymerase chain reaction to detect the presence of viral genetic material in the blood and confirm a diagnosis among patients. In some cases, if the infection affects specific organs or tissues, a biopsy may be recommended to obtain a sample for laboratory analysis and rule out other causes of the underlying symptoms.
The increasing prevalence of exposure to infected fluids through activities like kissing, sexual contact, sharing utensils or drinks, etc., is primarily driving the cytomegalovirus infections market. In addition to this, the rising cases of weakened immune systems, in which the number and function of white blood cells are reduced, resulting in a decreased ability to control diseases, is also creating a positive outlook for the market. Moreover, the widespread adoption of antiviral drugs, including ganciclovir, valganciclovir, foscarnet, etc., since they work by inhibiting the replication of the virus, is further bolstering the market growth. Apart from this, the escalating application of intravenous immunoglobulin therapy that modulates the body's defense system, thereby potentially reducing inflammation and preventing or minimizing organ damage, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hematopoietic stem cell transplants to treat the ailment, owing to their several associated benefits, such as effectively eliminating the viral load and improving overall patient outcomes, is expected to drive the cytomegalovirus infections market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cytomegalovirus infections market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cytomegalovirus infections and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cytomegalovirus infections market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cytomegalovirus infections market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cytomegalovirus infections market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cytomegalovirus infections marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cytomegalovirus infections market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cytomegalovirus infections market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cytomegalovirus infections market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections across the seven major markets?
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cytomegalovirus infections by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cytomegalovirus infections across the seven major markets?
What is the size of the cytomegalovirus infections patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cytomegalovirus infections?
What will be the growth rate of patients across the seven major markets?
Cytomegalovirus Infections: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cytomegalovirus infections drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cytomegalovirus infections market?
What are the key regulatory events related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by status related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by phase related to the cytomegalovirus infections market?
What is the structure of clinical trial landscape by route of administration related to the cytomegalovirus infections market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CYTOMEGALOVIRUS INFECTIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CYTOMEGALOVIRUS INFECTIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CYTOMEGALOVIRUS INFECTIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CYTOMEGALOVIRUS INFECTIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CYTOMEGALOVIRUS INFECTIONS - UNMET NEEDS
10 CYTOMEGALOVIRUS INFECTIONS - KEY ENDPOINTS OF TREATMENT
11 CYTOMEGALOVIRUS INFECTIONS - MARKETED PRODUCTS
11.1 List of Cytomegalovirus Infections Marketed Drugs Across the Top 7 Markets
11.1.1 Prevymis (Letermovir) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Valcyte (Valganciclovir) - Roche
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Livtencity (Maribavir) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CYTOMEGALOVIRUS INFECTIONS - PIPELINE DRUGS
12.1 List of Cytomegalovirus Infections Pipeline Drugs Across the Top 7 Markets
12.1.1 NPC21 - Nobelpharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Brincidofovir - Chimerix/Emergent Biosolutions
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 V160 - Merck & Co
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 mRNA 1647 - Moderna Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CYTOMEGALOVIRUS INFECTIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CYTOMEGALOVIRUS INFECTIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CYTOMEGALOVIRUS INFECTIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cytomegalovirus Infections - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cytomegalovirus Infections - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cytomegalovirus Infections - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cytomegalovirus Infections - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cytomegalovirus Infections - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cytomegalovirus Infections - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cytomegalovirus Infections - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cytomegalovirus Infections - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cytomegalovirus Infections - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cytomegalovirus Infections - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cytomegalovirus Infections - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cytomegalovirus Infections - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cytomegalovirus Infections - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cytomegalovirus Infections - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cytomegalovirus Infections - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cytomegalovirus Infections - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cytomegalovirus Infections - Access and Reimbursement Overview
16 CYTOMEGALOVIRUS INFECTIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CYTOMEGALOVIRUS INFECTIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CYTOMEGALOVIRUS INFECTIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CYTOMEGALOVIRUS INFECTIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CYTOMEGALOVIRUS INFECTIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CYTOMEGALOVIRUS INFECTIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CYTOMEGALOVIRUS INFECTIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CYTOMEGALOVIRUS INFECTIONS - UNMET NEEDS
10 CYTOMEGALOVIRUS INFECTIONS - KEY ENDPOINTS OF TREATMENT
11 CYTOMEGALOVIRUS INFECTIONS - MARKETED PRODUCTS
11.1 List of Cytomegalovirus Infections Marketed Drugs Across the Top 7 Markets
11.1.1 Prevymis (Letermovir) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Valcyte (Valganciclovir) - Roche
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Livtencity (Maribavir) - Takeda
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CYTOMEGALOVIRUS INFECTIONS - PIPELINE DRUGS
12.1 List of Cytomegalovirus Infections Pipeline Drugs Across the Top 7 Markets
12.1.1 NPC21 - Nobelpharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Brincidofovir - Chimerix/Emergent Biosolutions
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 V160 - Merck & Co
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 mRNA 1647 - Moderna Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CYTOMEGALOVIRUS INFECTIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CYTOMEGALOVIRUS INFECTIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CYTOMEGALOVIRUS INFECTIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cytomegalovirus Infections - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cytomegalovirus Infections - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cytomegalovirus Infections - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cytomegalovirus Infections - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cytomegalovirus Infections - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cytomegalovirus Infections - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cytomegalovirus Infections - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cytomegalovirus Infections - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cytomegalovirus Infections - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cytomegalovirus Infections - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cytomegalovirus Infections - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cytomegalovirus Infections - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cytomegalovirus Infections - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cytomegalovirus Infections - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cytomegalovirus Infections - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cytomegalovirus Infections - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cytomegalovirus Infections - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cytomegalovirus Infections - Access and Reimbursement Overview
16 CYTOMEGALOVIRUS INFECTIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CYTOMEGALOVIRUS INFECTIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CYTOMEGALOVIRUS INFECTIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
